Illinois Municipal Retirement Fund Has $3.24 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Illinois Municipal Retirement Fund trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 58.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,539 shares of the medical research company’s stock after selling 59,302 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Edwards Lifesciences were worth $3,244,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. RWA Wealth Partners LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $238,000. OLD National Bancorp IN boosted its holdings in shares of Edwards Lifesciences by 1.2% during the fourth quarter. OLD National Bancorp IN now owns 186,450 shares of the medical research company’s stock worth $14,217,000 after purchasing an additional 2,299 shares during the period. Commerzbank Aktiengesellschaft FI acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $218,000. Handelsbanken Fonder AB boosted its holdings in shares of Edwards Lifesciences by 21.6% during the fourth quarter. Handelsbanken Fonder AB now owns 1,610,182 shares of the medical research company’s stock worth $122,776,000 after purchasing an additional 286,095 shares during the period. Finally, Robbins Farley boosted its holdings in shares of Edwards Lifesciences by 38.2% during the fourth quarter. Robbins Farley now owns 19,654 shares of the medical research company’s stock worth $1,499,000 after purchasing an additional 5,436 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the sale, the vice president now owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now directly owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 in the last 90 days. 1.29% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price target for the company in a report on Friday, February 2nd. Evercore ISI lifted their target price on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Stifel Nicolaus lifted their target price on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. Citigroup lifted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Finally, Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.73.

Edwards Lifesciences Trading Up 1.0 %

Shares of EW stock opened at $88.62 on Thursday. The firm has a market capitalization of $53.34 billion, a P/E ratio of 38.53, a price-to-earnings-growth ratio of 4.35 and a beta of 1.05. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The firm’s fifty day simple moving average is $90.23 and its 200 day simple moving average is $78.69. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.64 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.